Catheter Precision Files 8-K with Voting Matters

TL;DR

CATAPTR filed an 8-K on Jan 13th covering voting matters and financials.

AI Summary

Catheter Precision, Inc. filed an 8-K on January 17, 2025, reporting on matters submitted to a vote of security holders and other events. The filing also includes financial statements and exhibits. The company was formerly known as Ra Medical Systems, Inc. before changing its name on September 8, 2017.

Why It Matters

This filing provides updates on corporate actions and financial information for Catheter Precision, Inc., which could impact investor decisions.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news.

Key Numbers

• 001-38677 — SEC File Number (Identifies the company's filing history)
• 38-3661826 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• Ra Medical Systems, Inc. (company) — Former company name
• January 13, 2025 (date) — Earliest event reported date
• January 17, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• SC (state) — Principal executive offices state

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock , par value $0.0001 per share VTAK NYSE American Indica

Filing Documents

• vtak20250114_8k.htm (8-K) — 46KB
• ex_765813.htm (EX-5.1) — 27KB
• 0001437749-25-001385.txt ( ) — 214KB
• vtak-20250113.xsd (EX-101.SCH) — 3KB
• vtak-20250113_def.xml (EX-101.DEF) — 12KB
• vtak-20250113_lab.xml (EX-101.LAB) — 15KB
• vtak-20250113_pre.xml (EX-101.PRE) — 12KB
• vtak20250114_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On January 13, 2025, the Company held a Special Meeting of stockholders at which, of the 8,004,633 shares of the Company's common stock outstanding as of November 18, 2024, the record date for the Special Meeting, 4,184,744 shares of common stock were represented, either in person or by proxy, constituting, of the shares entitled to vote, approximately 52.3% of the outstanding shares of common stock. At the Special Meeting, the Company's stockholders considered five proposals, which are described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on November 25, 2024. The matters voted on at the Special Meeting and the votes cast with respect to each such matter are set forth below: 1. Proposal No. 1: To approve, in accordance with NYSE American Company Guide Section 713(a), the issuance of up to 10,695,962 shares of our outstanding common stock, par value $0.0001 per share, upon the exercise of our Series K Common Stock Purchase Warrants. Proposal No. 1 was approved, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,432,775 833,825 12,772 1,905,372 2. Proposal No. 2: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from thirty (30) million shares to sixty (60) million. Proposal No. 2 was approved, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 2,823,644 1,358,738 2,362 0 3. Proposal No. 3: To approve an additional 1.5 million shares of common stock for issuance pursuant to our 2023 Equity Incentive Plan. Proposal No. 3 was approved, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,842,338 426,114 10,920 1,905,372 4. Proposal No. 4: To ratify the appointment of WithumSm

01. Other Events

Item 8.01. Other Events. The opinion of Arnall Golden Gregory LLP dated January 10, 2025 and filed with the Company's registration statement on Form S-3 (No. 333-284217) on January 10, 2025 included an assumption that the Company's stockholders would approve, at the special meeting of stockholders to be held on January 13, 2025 or any adjournment thereof, an amendment to increase the Company's authorized Common Stock from 30 million shares to 60 million shares and that such amendment would be filed with the Secretary of State of Delaware and become effective. Those events have occurred as assumed and a revised opinion of Arnall Golden Gregory LLP that removes that assumption is filed as Exhibit 5.1 hereto.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 5.1 Opinion of Arnall Golden Gregory LLP dated January 13, 2025 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: January 17, 2025 By: /s/ Philip Anderson Philip Anderson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR